MeiraGTx Holdings plc
Category: AI in Healthcare
A vertically integrated gene therapy company developing innovative treatments for serious diseases, including neurologic disorders, inherited retinal diseases, and conditions such as radiation-induced xerostomia. MeiraGTx Holdings plc was founded in 2015. The company is led by Alexandria 'Zandy' Forbes, Ph.D.. Based in London and New York. Team size: N/A. Total funding raised: $430M. Latest round: Strategic collaboration with Hologen AI featuring a $200 million upfront payment and an additional $230 million committed via joint venture (March 2025). Key investors include Hologen AI.
- Founded
- 2015
- Headquarters
- London and New York
- Team size
- N/A
- Total funding
- $430M
Value proposition
Delivers cost-effective, locally administered gene therapies using a proprietary manufacturing platform and innovative riboswitch gene regulation technology for precise control of gene expression.
Products and solutions
AAV-GAD for Parkinson’s disease, AAV-BDNF for genetic obesity, Therapy for radiation-induced xerostomia
Unique value
Proprietary end-to-end manufacturing platform combined with a transformative riboswitch gene regulation technology.
Target customer
Patients with both inherited and non-inherited diseases affecting the eye, CNS, and salivary gland function
Industries served
Biotechnology, Healthcare, Gene Therapy
Technology advantage
Full in-house production capabilities with innovative viral vector and riboswitch design enabling precise, dose-responsive control of gene expression.
How they differentiate
Focus on both inherited and non-inherited diseases with a vertically integrated manufacturing platform that reduces costs and enhances delivery, setting it apart from competitors relying on outsourcing.
Main competitors
Spark Therapeutics, Biogen, uniQure
Key partnerships
Hologen AI, Janssen Pharmaceuticals, Inc.
Major milestones
Entered strategic collaboration with Hologen AI to expedite Phase 3 development of AAV-GAD Filed for a public offering (e.g., an $86 million IPO) Established strategic clinical and manufacturing partnerships, including with Janssen Pharmaceuticals, Inc.
Growth metrics
Expanded in-house multi-facility GMP manufacturing capabilities and advancement of multiple late-stage clinical programs; strengthened market confidence reflected by significant stock surges following strategic deals
Market positioning
Positioned as a leader in genetic medicine innovation and manufacturing with robust clinical and regulatory pipelines.
Geographic focus
Global, with significant operations in the US and Europe
Patents and IP
Key proprietary technologies are protected by a portfolio of patents and intellectual property, though specific details are not publicly disclosed.
About Alexandria 'Zandy' Forbes, Ph.D.
Alexandria 'Zandy' Forbes, Ph.D., has served as the President and Chief Executive Officer of MeiraGTx since she co-founded the company in March 2015. She has a deep background in biotech investment and drug development, having spent a decade as a healthcare investor at Sivik Global Partners and Meadowvale Partners. Prior to her career in finance, she earned a Ph.D. in Molecular Genetics from the University of Oxford and held several post-doctoral and research fellow positions at institutions including the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center, Duke University, and the Carnegie Institute at Johns Hopkins University.
Official website: https://www.meiragtx.com/